Latest stories on PSTV
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
Business Insider56 · neutralproduct/pr
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Business Insider63 · neutralproduct/pr
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
Business Insider56 · neutralproduct/pr
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Business Insider63 · neutralproduct/pr
Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript
Seeking Alpha55 · neutralgeneral
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)
Yahoo Top50 · neutralgeneral
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding | PSTV Stock News
StockTitan55 · neutralgeneral
Plus Therapeutics wins Elevance Health coverage deal
Seeking Alpha68 · bullishproduct/pr
Plus Therapeutics to Provide Business Update Call on June 30, 2026 | PSTV Stock News
StockTitan50 · neutralgeneral
Plus Therapeutics Launches New At-The-Market Equity Program
TipRanks28 · bearishgeneral
PLUS THERAPEUTICS, INC. (PSTV) files 8-K
SEC 8-K50 · neutralgeneral
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory | PSTV Stock News
StockTitan63 · neutralproduct/pr
Plus Therapeutics Taps AI Partnership to Advance CNS Oncology Platform—Integration with Ephemeral Targets Precision and Efficiency Gains
MarketChameleon67 · bullishproduct/pr
Plus Therapeutics GAAP EPS of -$1.05 misses by $0.15, revenue of $1.03M beats by $0.06M
Seeking Alpha34 · bearishearnings